Share chart Kadmon Holdings, Inc.
Extended chart
Simple chart
About
Kadmon Holdings, Inc., биофармацевтическая компания, обнаруживает, разрабатывает и продает малые молекулы и биопрепараты, прежде всего, для лечения воспалительных и фиброзных заболеваний.
More detailsP/S | 134.95 |
---|---|
P/BV | 2.13 |
EV/EBITDA | 0.0436 |
EBITDA | -0.1265 |
Цена ао | 9.5 |
Сайт | http://www.kadmon.com |
Число акций ао | 166 млн |
Выручка | 0.0261 |
Див.доход ао | 0 |
ISIN | US48283N1063 |
Валюта | usd |
IPO date | 2016-07-27 |
Sector | Health Care |
Industry | Biotechnology |
Валюта отчета | usd |
Change price per day: | 0% (9.5) |
---|---|
Change price per week: | 0% (9.5) |
Change price per month: | 0% (9.5) |
Change price per 3 month: | 0% (9.5) |
Change price per half year: | 0% (9.5) |
Change price per year: | 0% (9.5) |
Change price per 3 year: | 0% (9.5) |
Change price per 5 year: | +112.05% (4.48) |
Change price per year to date: | 0% (9.5) |
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
Head | Job title | Payment | Year of birth |
---|---|---|---|
Dr. Harlan W. Waksal | Pres, CEO & Director | 1.22M | 1953 (71 year) |
Mr. Steven Meehan | Exec. VP & CFO | 830k | 1965 (59 years) |
Mr. Gregory S. Moss Esq. | Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer | 709.88k | 1984 (40 years) |
Mr. Kyle Carver | Sr. VP, Chief Accounting Officer & Controller | N/A | |
Ellen Cavaleri | Director of Investor Relations | N/A | |
Mr. Sanjay Aggarwal | Sr. VP of Clinical Devel. | N/A | |
Ms. Haya Taitel M.S., R.Ph. | Sr. VP & Chief Commercial Officer | N/A | |
Dr. John L. Ryan M.D., Ph.D. | Exec. VP and Exec. Medical Director of Clinical & Regulatory Devel. | 1943 (81 year) | |
Dr. Jeegar Patel | Sr. VP of Research & Non-Clinical Devel. |
Address: United States, New York, NY , 450 East 29th Street - open in Google maps, open in Yandex maps
Website: http://www.kadmon.com
Website: http://www.kadmon.com